查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863323

真菌感染疾病診斷市場：依診斷技術、最終用戶、檢體類型、病原體類型和檢測方式分類－2025-2032年全球預測

Fungal Infections Diagnosis Market by Diagnostic Technology, End User, Specimen Type, Pathogen Type, Testing Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，真菌感染疾病診斷市場將成長至 38.9 億美元，複合年成長率為 7.17%。

關鍵市場統計數據
基準年 2024 22.3億美元
預計年份：2025年 24億美元
預測年份 2032 38.9億美元
複合年成長率 (%) 7.17%

全面介紹現代真菌診斷、臨床負擔、診斷缺口以及對更快更準確檢測方法的需求

真菌感染疾病的臨床和診療緊迫性日益凸顯，因為這些病原體在各種醫療環境中持續引發診斷難題。臨床醫生面臨持續的挑戰，因為真菌感染疾病的症狀通常與細菌和病毒感染相似，但所需的治療策略卻截然不同。診斷延遲或不準確會直接導致患者預後不良、住院時間延長以及抗菌藥物抗藥性風險增加，所有這些都凸顯了快速、準確診斷的重要性。

在此背景下，診斷領域的相關人員正在探索一套快速發展的套件，涵蓋從傳統培養方法到先進的分子和蛋白質體學平台。實驗室和醫院正在權衡基於培養方法的可靠性、分子診斷的快速性以及質譜技術的通量優勢。同時，就地檢驗正逐漸成為集中式工作流程的補充，尤其是在門診和資源匱乏的環境中，快速決策至關重要。

隨著診斷技術的日益多樣化，決策者必須在預算有限且複雜的報銷機制下，仔細權衡分析性能、臨床效用、通量和成本。因此，臨床實驗室、研究機構和醫院網路都在優先考慮符合自身能力和病患群體需求的實施方案。本導言旨在為後續分析提供框架，重點闡述影響真菌診斷近期投資和政策選擇的臨床需求、技術權衡和營運考量。

分子診斷、蛋白質體學、自動化、就地檢驗和數據驅動的臨床整合方面的進步正在改變真菌診斷模式。

由於技術、操作和數據驅動等多面向因素的融合，真菌診斷領域正經歷變革性的轉變。分子診斷技術加速了從表現型鑑定向基因型和序列表徵的轉變，不僅實現了病原體的快速檢測，還提供了更豐富的抗藥性決定因素和菌株水平突變資訊。同時，MALDI-TOF MS等質譜技術透過縮短鑑定時間和減少技術人員的操作時間，重新定義了實驗室工作流程；而顯微鏡和培養流程的改進則持續提供關鍵的確認性診斷和藥敏試驗數據。

除了檢測效能之外，自動化和實驗室資訊學正在集中資料流，並實現分散式檢查實驗室網路中更一致的工作流程。實驗室資訊系統與臨床決策支援的整合正在改善結果解讀，並促進更具可操作性的報告，從而縮短從檢測到治療最佳化的時間。同時，就地檢驗和側向層析免疫檢測的成熟正在將診斷範圍擴展到門診和急診科，使患者能夠即時獲得檢測結果，從而做出及時的抗真菌藥物治療決策。

定序技術的進步，特別是次世代定序（NGS）調查方法的進步，為全面分析病原體和集體爆發調查開闢了新的可能性。 NGS化學方法的改進、平台可用性的提高以及生物資訊學流程的完善，使得診斷實驗室能夠利用深度定序來表徵複雜的感染疾病和混合感染族群。然而，當臨床問題較為具體且結果出爐時間至關重要時，透過即時PCR或常規PCR進行標靶快速檢測仍不可或缺。

最後，將數位健康工具和人工智慧整合到真菌診斷中，正開始影響基於影像的解讀、預測風險分層和工作流程最佳化。這些變化並非只是漸進式的改進，而是診斷路徑的重構，速度、特異性和整合資料輸出的重要性日益凸顯，並逐漸決定臨床應用和實驗室投資的優先順序。

評估2025年美國關稅對全球真菌診斷供應鏈、採購經濟和創新軌蹟的累積影響

關稅等政策措施會對診斷供應鏈、採購慣例和創新生態系統產生深遠且有時被低估的連鎖反應。 2025年，美國對某些進口商品徵收關稅，影響了真菌檢測流程中必不可少的診斷設備、耗材和試劑的成本結構。對於依賴全球供應商網路的臨床實驗室和醫院系統而言，進口成本的增加正在影響其採購決策，並加速其供應商關係多元化的進程。

採購團隊正在透過審查供應商組合、盡可能合併訂單以及尋找國內關鍵零件製造商來應對關稅帶來的價格波動風險。這些調整會對營運產生影響：檢驗的替代供應商必須重新獲得資格，產品替代可能會影響工作流程效率和診斷的連續性。在研究環境中，試劑成本的上漲使研究設計和預算編制變得更加複雜，這可能會減緩轉化研究的進展，並延遲產生可用於支援臨床應用的檢驗數據。

關稅也在影響製造商的創新策略。一些供應商正透過投資近岸外包和本地製造來重組供應鏈，以確保產品供應並保持價格競爭力。另一些供應商則加速產品系列轉型，轉向更節能高效的平台和整合系統，從而減少對高關稅組件的依賴。從市場觀點，這些變化可能會影響實驗室向下一代平台遷移的速度，並重塑客戶與供應商之間關於基於數量的定價和多年服務合約的談判結構。

重點，監管和報銷框架將與關稅的影響相互作用。除非臨床療效得到明確證實，否則醫療支付者和醫院可能會推遲核准高成本的診斷產品，這凸顯了進行可靠的臨床效用研究的重要性。摘要，關稅正在促使各方在採購、檢驗、生產策略和證據生成等方面做出多方面的應對，而那些積極調整供應鏈和臨床證據策略的相關人員將更有利於維持服務品質和創新勢頭。

關鍵細分洞察，整合診斷技術、最終用戶、檢體類型、病原體譜和檢測模式，指南策略優先排序。

要了解市場，需要對診斷技術進行詳細分析，並了解每種方法如何應用於臨床案例和實驗室實踐。以培養為基礎的方法是許多實驗室的臨床基石，液體和固態培養基培養為基於生長的確認和抗真菌藥物敏感性測試提供了機會。免疫檢測（包括酵素連結免疫吸附試驗 (ELISA) 平台和橫向流動化驗）透過抗原和抗體檢測支持快速臨床分流和監測，這在資源有限和照護現場環境中尤其有用。基質輔助雷射解吸電離飛行時間質譜 (MALDI-TOF MS) 可顯著縮短培養分離株的鑑定時間，從而減少人力投入並加快後續臨床決策。在許多醫療機構中，顯微鏡檢查仍然是快速初步診斷的關鍵，尤其是在形態學觀察支持即時選擇治療方案的情況下。分子診斷涵蓋了次世代定序(NGS) 和聚合酵素鏈鎖反應(PCR) 的方法。在新一代定序（NGS）領域， 定序和 Ion Torrent定序在讀取準確性、通量和運行時間方面提供了互補的優勢，從而能夠進行全面的病原體分析和疫情爆發分析。在 PCR 領域，常規和即時聚合酵素鏈鎖反應聚合酵素鏈鎖反應可在既定的臨床工作流程中提供高度定向和靈敏的檢測。

最終用戶包括診斷實驗室、醫院/診所和研究機構，它們在技術應用和投資方面各有不同的動機。診斷實驗室優先考慮兼顧通量、單次檢測成本和與實驗室資訊系統整合性的平台。而醫院和診所則傾向於能夠快速獲得結果、直接影響病患管理的方案。研究機構則優先考慮表徵的深度和探索性檢測的靈活性，並且通常是先進定序和蛋白質組學方法的早期採用者。

檢體類型，包括血液、腦脊髓液、痰液、組織和尿液，決定了分析要求和分析前流程。鑑於感染疾病和中樞神經系統感染疾病的臨床嚴重，血液和腦脊髓液檢測需要高靈敏度的分析方法和嚴格的污染控制。呼吸道檢體，例如痰液和組織樣本，涉及更複雜的檢體處理，通常受益於結合培養和分子檢測的工作流程。尿液檢查在侵襲性疾病中較少見，但在某些監測和門診環境中非常有用。

按病原體類型（麴菌症、念珠菌症、隱球菌病、皮膚絲狀菌症和白黴菌症）進行分類，可指導診斷靶向，因為每種屬和臨床症候群都存在不同的分析挑戰、抗藥性特徵和檢體選擇偏好。檢測模式涵蓋臨床檢測、就地檢驗和僅用於研究的應用，反映了從臨床可操作診斷到探索性和研究性檢測的頻譜。綜合考慮這些分類維度，可以指導技術開發、監管規劃和商業化路徑的策略優先排序，因為靈敏度、速度和操作適用性之間的權衡因細分指南和用戶群體而異。

區域趨勢和競爭定位（美洲、歐洲、中東和非洲、亞太地區）重點關注採用率、監管和容量趨勢

區域趨勢既影響技術採納的速度，也影響診斷服務提供的結構。在美洲，高通量參考實驗室和綜合醫療系統推動了對高通量平台和整合工作流程的需求，而強大的臨床研究網路則支援路徑檢驗以及定序和質譜技術的早期應用。然而，由於報銷機制的複雜性和區域採購模式的限制，在三級醫療中心以外的廣泛推廣之前，必須明確證明其臨床效用和成本效益。

歐洲、中東和非洲地區醫療基礎設施的多樣性造成了市場結構的兩極化。儘管都市區和三級醫療機構的先進實驗室已部署了尖端的分子和蛋白質組學平台，但許多機構仍依賴傳統的培養和免疫檢測流程。歐洲部分地區的監管協調工作將有助於跨境應用，但整個地區報銷環境的差異和檢測能力的差異，使得產品設計需要適應性強，並提供有針對性的實施支援。

在亞太地區，對檢測能力的快速投資以及對感染疾病防治的日益重視，為集中式和分散式診斷技術的發展創造了有利條件。該地區的市場動態受到大規模公共醫療採購和私人實驗室擴張的雙重驅動，這為能夠擴大供應規模並提供培訓和檢驗支援的製造商創造了機會。在所有地區，在地化生產、供應鏈韌性和監管一致性正日益成為影響採購週期和新技術融入常規臨床實踐速度的關鍵因素。

真菌診斷生態系統主要企業的企業資料和策略，包括創新路徑、夥伴關係和商業化策略。

競爭格局呈現出多元化的特點，既有成熟的儀器和試劑製造商，也有專業的分子和定序平台提供者、受託研究機構，以及新興的軟體和數據分析公司。市場領導憑藉整合解決方案脫穎而出，這些方案將強大的儀器平台與檢驗的耗材、軟體驅動的工作流程編排以及能夠減輕客戶檢驗負擔的服務協議相結合。中型公司則通常專注於針對特定實驗室領域、照護現場模式或經濟高效的耗材模式的利基檢測產品。

策略聯盟和經銷夥伴十分普遍，使公司能夠拓展地域覆蓋範圍，並整合互補技術，例如將質譜鑑定系統與分子抗藥性檢測相結合。此外，Start-Ups公司正專注於一些創新領域，例如簡化樣品製備、提高靈敏度的快速側向層析技術以及簡化NGS分析的生物資訊工具。合約實驗室和參考檢測網路作為早期採用者和檢驗發揮關鍵作用，為新技術展現臨床效用並促進其在實驗室中的廣泛應用鋪平了道路。

一個清晰的趨勢正在顯現：投資於證據生成、監管合規準備和可擴展服務模式的公司，在與醫療系統簽訂長期合約方面佔據優勢。此外，能夠提供培訓、遠端支援以及與實驗室資訊系統 (LIS) 整合的公司，可以減輕客戶負擔並加速產品應用。競爭優勢越來越取決於能否提供端到端的解決方案，全面應對分析性能、營運效率、實驗室檢驗和臨床醫生應用等方面的實際挑戰。

為產業領導者提供切實可行的建議，以加速臨床應用、加強供應鏈、最佳化產品組合併在診斷領域創造價值。

產業領導者應優先採取一系列策略行動，在控制營運風險的同時，加速臨床應用。首先，投資進行有針對性的臨床效用研究，將診斷結果與可操作的治療決策和可衡量的患者療效聯繫起來。強力的臨床證據將降低支付方的阻力，並支持更廣泛的應用。其次，實現供應鏈多元化，並考慮區域性生產和策略性庫存緩衝，以降低關稅和物流風險。這將確保即使在政策變動期間，檢測服務的持續性。

第三，我們將透過提供模組化平台，使產品開發與終端用戶的工作流程保持一致，該平台既能滿足高通量集中檢測的需求，也能滿足快速照護現場的需求。這種方法將增加可套用場景的數量，並使實驗室能夠根據自身的偵測量擴展應用規模。第四，我們將透過加強與參考實驗室和臨床網路的合作，加快產品推廣速度，從而促進第三方檢驗、早期應用案例記錄和臨床醫生培訓。第五，我們將把軟體主導的價值提案（例如連接性、結果解讀和工作流程自動化）融入我們的產品中，以減輕實驗室的負擔，並提高檢測結果對臨床醫生的效用。

最後，應積極主動地與監管機構和支付方溝通，在研發初期就明確證據要求和報銷途徑。預先考慮監管和報銷方面的問題，並將真實世界證據的收集納入產品上市流程，可以加快產品上市速度，並減少推廣應用的障礙。這些措施共同建構了一個穩健的商業策略，在創新、證據生成和業務連續性之間取得了平衡。

透明的調查方法，清楚地概述了主要和次要調查方法、資料三角驗證、檢驗通訊協定以及支撐分析的分析限制。

本分析基於混合方法研究，整合了初步質性研究、系統性二手證據回顧和三角驗證。初步研究包括對臨床實驗室技術人員、醫院採購人員、研究人員和行業高管進行結構化訪談，以收集有關工作流程、檢驗障礙和推廣促進因素的經驗性見解。二手研究涵蓋同行評審文獻、監管指導文件、臨床實踐指南和技術白皮書，以闡明初步研究結果並檢驗分析假設。

數據三角測量法用於整合不同的輸入數據，並識別相關人員群體和證據來源之間的一致模式。透過技術映射和能力評估，使平台屬性與臨床應用案例和實驗室操作限制相符。此外，對臨床試驗註冊資訊和專利申請的審查，補充了對新興檢測方法的創新軌跡和未來展望。

本研究認知到定性資料和二手資料固有的局限性，包括區域報告差異、不斷變化的監管環境以及技術發展與臨床檢驗發表之間的時間滯後。為彌補這些局限性，分析重點關注已證實的主題，並區分觀察到的實踐與理想能力。在適當情況下，我們會考慮區域差異和機構能力，以確保建議在不同的醫療環境中均具有可操作性。

簡潔扼要的結論總結了臨床醫生、實驗室主任、投資者和政策制定者在應對不斷變化的真菌診斷格局方面所應遵循的原則。

隨著技術創新、供應鏈重組和實證實踐的融合，真菌診斷正在經歷一場深刻的變革，重塑臨床實踐。實驗室和醫療機構面臨複雜的抉擇，需要在分析績效、營運實際情況和支付方期望之間取得平衡。隨著分子和蛋白質體學平台日趨成熟，就地檢驗的普及，成功的解決方案不僅要展現出切實的臨床效益，還要能夠無縫整合到現有工作流程中。

政策和採購因素，例如關稅和區域製造業趨勢，將繼續影響投資和應用模式。積極應對這些因素的相關人員，例如透過多元化採購、策略聯盟和重點證據生成，可以維持診斷服務的連續性並加速創新技術的應用。最終，將製造商、臨床領導者和醫療系統聚集在一起，共同檢驗、採用和最佳化真菌感染疾病診斷路徑的協作方式，將是持續進展的關鍵。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將快速分子診斷試劑盒整合到醫院常規診療流程中，以實現真菌病原體的檢測。
  • 利用次世代定序技術全面鑑定罕見和抗藥性真菌物種
  • 開發用於門診早期檢測侵襲性真菌感染疾病的即時免疫檢測照護現場
  • 對能夠同時檢測臨床檢體中多種真菌病原體的多重PCR技術的需求日益成長
  • 擴展遠端醫療平台，整合遠距離診斷工具，用於監測慢性真菌感染疾病
  • 人們對床邊檢測HIV患者隱球菌抗原的橫向流動化驗越來越感興趣
  • 監管核准和報銷政策促進了新型BETA-D-聚葡萄糖診斷測試的市場准入

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 真菌感染疾病診斷市場（依診斷技術分類）

  • 培養方法
    • 液體培養基培養
    • 固體培養基培養
  • 免疫檢測
    • ELISA
    • 橫向流動化驗
  • MALDI TOF MS
  • 顯微鏡
  • 分子診斷
    • 次世代定序
      • Illumina定序
      • 離子流定序
    • 聚合酵素鏈鎖反應
      • 常規聚合酵素鏈鎖反應
      • 即時聚合酵素鏈鎖反應

第9章 依最終用戶分類的真菌感染疾病診斷市場

  • 診斷實驗室
  • 醫院和診所
  • 研究所

第10章：依檢體類型分類的真菌感染疾病診斷市場

  • 血
  • 腦脊髓液
  • 痰
  • 組織
  • 尿

第11章 以病原體類型分類的真菌感染疾病診斷市場

  • 麴菌症
  • 念珠菌症
  • 隱球菌病
  • 皮膚絲狀菌症
  • 白黴菌症

第12章 依檢測方法分類的真菌感染疾病診斷市場

  • 實驗室檢測
  • 就地檢驗
  • 僅供研究使用

第13章 真菌感染疾病診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 真菌感染疾病診斷市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國真菌感染疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Abbott Laboratories
    • bioMerieux SA
    • Becton, Dickinson and Company
    • Bruker Corporation
    • DiaSorin SpA
    • QIAGEN NV
    • Siemens Healthineers AG
    • Fujirebio Holdings, Inc.
Product Code: MRR-346757DFA1E9

The Fungal Infections Diagnosis Market is projected to grow by USD 3.89 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.23 billion
Estimated Year [2025] USD 2.40 billion
Forecast Year [2032] USD 3.89 billion
CAGR (%) 7.17%

Comprehensive introduction to contemporary fungal diagnostics, framing clinical burdens, diagnostic gaps, and the imperative for faster, more precise detection

The clinical and operational urgency around fungal infections has intensified as these pathogens continue to present diagnostic complexity across diverse care settings. Clinicians face a persistent challenge: fungal disease often mimics bacterial and viral syndromes while requiring fundamentally different therapeutic strategies. Delays or inaccuracies in diagnosis translate directly into adverse patient outcomes, extended hospital stays, and amplified antimicrobial resistance risks, which together raise the stakes for faster and more precise diagnostics.

Against this backdrop, diagnostic stakeholders are navigating a rapidly evolving toolkit that spans traditional culture methods to advanced molecular and proteomic platforms. Laboratories and hospitals are balancing the reliability of culture-based approaches with the speed advantages of molecular diagnostics and the throughput benefits of mass spectrometry technologies. At the same time, point-of-care testing is emerging as a complement to centralized workflows, particularly in outpatient and resource-limited environments where rapid decision-making is critical.

As diagnostic technologies diversify, decision-makers must weigh analytical performance, clinical utility, throughput, and cost within constrained budgets and complex reimbursement landscapes. Clinical laboratories, research institutes, and hospital networks are therefore prioritizing adoption pathways that align with institutional capabilities and patient populations. This introduction frames the subsequent analysis by highlighting the clinical imperatives, technology trade-offs, and operational considerations that will shape near-term investment and policy choices in fungal diagnostics.

Transformative shifts in fungal diagnostic landscape driven by molecular advances, proteomics, automation, point-of-care evolution, and data-driven clinical integration

The landscape of fungal diagnostics is undergoing transformative shifts driven by converging technological, operational, and data-centric forces. Molecular diagnostics have accelerated the move from phenotype-based identification toward genotypic and sequence-based characterization, enabling not only quicker pathogen detection but also richer information about resistance determinants and strain-level variation. Concurrently, mass spectrometry technologies such as MALDI TOF MS have redefined laboratory workflows by compressing identification timelines and reducing hands-on technician time, while improvements in microscopy and culture workflows continue to provide essential confirmatory and susceptibility data.

Beyond assay performance, automation and laboratory informatics are centralizing data flows and enabling more consistent workflows across decentralized laboratory networks. Integration of laboratory information systems with clinical decision support is improving result interpretation and driving more actionable reporting, thereby shortening the time from detection to therapy optimization. In parallel, the maturation of point-of-care modalities and lateral flow immunoassays is expanding diagnostic reach into outpatient clinics and emergency departments, where immediate results can drive timely antifungal stewardship decisions.

Advances in sequencing, particularly in Next Generation Sequencing methodologies, are unlocking new capabilities for comprehensive pathogen profiling and outbreak investigation. Improvements in NGS chemistry, platform accessibility, and bioinformatics pipelines are making deep sequencing feasible for diagnostic laboratories seeking to characterize complex infections or mixed populations. At the same time, real-time PCR and conventional PCR remain indispensable for targeted, rapid detection when clinical questions are narrow and turnaround time is critical.

Finally, the integration of digital health tools and artificial intelligence into fungal diagnostics is beginning to influence image-based interpretation, predictive risk stratification, and workflow optimization. Together, these shifts are not incremental; they represent a reconfiguration of diagnostic pathways, where speed, specificity, and integrated data outputs will increasingly determine clinical adoption and laboratory investment priorities.

Assessing the cumulative impact of United States tariffs in 2025 on global fungal diagnostics supply chains, procurement economics, and innovation trajectories

Policy instruments such as tariffs can have broad and sometimes underappreciated ripple effects across diagnostic supply chains, procurement practices, and innovation ecosystems. In 2025, United States tariffs introduced on selected imports are influencing cost structures for diagnostic instruments, consumables, and reagents that are integral to fungal testing workflows. For clinical laboratories and hospital systems that rely on global supplier networks, incremental import costs are shaping purchasing decisions and accelerating efforts to diversify vendor relationships.

Procurement teams are responding by recalibrating supplier mixes, increasing order consolidation where possible, and exploring domestic manufacturers for critical components to mitigate exposure to tariff-driven price volatility. These adaptations carry operational implications: validated alternative suppliers require requalification, and product substitutions can affect workflow efficiency and diagnostic continuity. In research settings, higher reagent costs are complicating study design and budget planning, which in turn can slow translational research efforts and delay the generation of clinical validation data that underpins adoption.

Tariffs are also influencing innovation strategies among manufacturers. Some vendors are reshaping supply chains through near-shoring and localized manufacturing investments to preserve competitive pricing while maintaining product availability. Others are accelerating product portfolios toward consumable-efficient platforms or integrated systems that reduce dependency on high-tariff components. From a market perspective, these shifts may alter the pace at which laboratories upgrade to next-generation platforms, and they may reshape negotiations between customers and suppliers around volume-based pricing and multi-year service agreements.

Importantly, regulatory and reimbursement frameworks interact with tariff impacts. Healthcare payers and hospitals may be slower to approve higher-cost diagnostics absent clear evidence of improved clinical outcomes, which places a premium on robust clinical utility studies. In summary, tariffs are prompting a multi-dimensional response that spans procurement, validation, manufacturing strategy, and evidence generation, and stakeholders that proactively adapt their supply chain and clinical evidence strategies will be better positioned to sustain service quality and innovation momentum.

Key segmentation insights synthesizing diagnostic technologies, end users, specimen types, pathogen profiles, and testing modes to guide strategic prioritization

Understanding the market requires a granular view of diagnostic technologies and how each modality maps to clinical use cases and laboratory operations. Culture Based approaches remain the clinical backbone for many laboratories, with liquid broth culture and solid media culture providing growth-based confirmation and the opportunity for antifungal susceptibility testing. Immunoassays, including Elisa platforms and lateral flow assay formats, deliver antigen and antibody detection that supports rapid clinical triage and surveillance, particularly in resource-constrained or point-of-care settings. MALDI TOF MS has materially lowered time-to-identification for cultured isolates, reducing labor and accelerating downstream clinical decision-making. Microscopy continues to be indispensable for rapid presumptive diagnosis in many care environments, particularly when morphology informs immediate therapeutic choices. Molecular Diagnostics encompass both Next Generation Sequencing and Polymerase Chain Reaction based approaches. Within NGS, Illumina Sequencing and Ion Torrent Sequencing offer complementary trade-offs between read accuracy, throughput, and run time, enabling comprehensive pathogen profiling and outbreak analytics. Within PCR, Conventional Polymerase Chain Reaction and Real Time Polymerase Chain Reaction provide targeted, highly sensitive detection with well-established clinical workflows.

End users include Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes, each with distinct drivers for technology adoption and investment. Diagnostic laboratories prioritize platforms that balance throughput, cost-per-test, and integration with laboratory information systems, while hospitals and clinics often favor rapid-turnaround modalities that can directly influence patient management. Research institutes focus on depth of characterization and flexibility for exploratory assays, often serving as early adopters for advanced sequencing and proteomic methods.

Specimen types such as blood, cerebrospinal fluid, sputum, tissue, and urine frame analytical requirements and pre-analytical workflows. Blood and cerebrospinal fluid demand assays with high analytical sensitivity and contamination control given the clinical severity of bloodstream and central nervous system infections. Respiratory specimens like sputum and tissue samples introduce complexity in sample processing and often benefit from combined culture and molecular workflows. Urine-based testing, while less common for invasive disease, is valuable in certain surveillance and outpatient contexts.

Pathogen-type segmentation-including Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis-drives diagnostic target selection, as each genus and clinical syndrome has different analytic challenges, resistance profiles, and specimen preferences. Testing modes span Laboratory Testing, Point Of Care Testing, and Research Use Only applications, reflecting the spectrum from clinically actionable diagnostics to exploratory and investigational assays. Taken together, these segmentation dimensions inform strategic prioritization for technology development, regulatory planning, and commercialization pathways, as trade-offs between sensitivity, speed, and operational fit differ across each segment and user class.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption, regulation, and capacity trends

Regional dynamics shape both the pace of technology adoption and the structure of diagnostic service delivery. In the Americas, high-capacity reference laboratories and integrated health systems drive demand for high-throughput platforms and consolidated workflows, while strong clinical research networks support pathway validation and early adoption of sequencing and mass spectrometry. Reimbursement complexity and regional procurement models, however, require clear demonstration of clinical utility and cost-effectiveness to support widespread deployment beyond tertiary centers.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure results in a dual market pattern: advanced laboratories in urban centers and tertiary hospitals adopt cutting-edge molecular and proteomic platforms, while many settings continue to rely on robust culture and immunoassay workflows. Regulatory harmonization efforts in parts of Europe facilitate cross-border adoption, but diverse reimbursement landscapes and variable laboratory capacity in the broader region necessitate adaptable product designs and targeted implementation support.

In Asia-Pacific, rapid investments in laboratory capacity and a growing focus on infectious disease preparedness are creating fertile conditions for both centralized and decentralized diagnostics. Market dynamics in this region are influenced by a mix of large public health procurements and private sector laboratory expansion, offering opportunities for manufacturers that can scale supply and provide training and validation support. Across all regions, local manufacturing, supply chain resilience, and regulatory alignment are increasingly decisive factors that affect procurement cycles and the speed at which new technologies are integrated into routine practice.

Corporate intelligence and key company strategies shaping the fungal diagnostics ecosystem including innovation pathways, partnerships, and commercialization playbooks

The competitive landscape is characterized by a mix of established instrument and reagent manufacturers, specialized molecular and sequencing platform providers, contract research organizations, and emergent software and data analytics firms. Market leaders are differentiating through integrated solutions that combine robust instrument platforms with validated consumables, software-enabled workflow orchestration, and service agreements that reduce customer validation burdens. Mid-tier players often compete on niche assays, point-of-care formats, or cost-effective consumable models that fit specific laboratory segments.

Strategic collaborations and distribution partnerships are common, enabling companies to extend geographic reach and couple complementary technologies-such as linking a mass spectrometry identification system with a molecular resistance assay. Additionally, start-ups are introducing focused innovations in areas such as simplified sample preparation, rapid lateral flow formats with enhanced sensitivity, and bioinformatics tools that streamline NGS interpretation. Contract laboratories and reference testing networks play a pivotal role as early adopters and validators, providing pathways for new technologies to demonstrate clinical utility and drive broader laboratory adoption.

A clear pattern emerges where companies that invest in evidence generation, regulatory preparedness, and scalable service models are better positioned to secure long-term contracts with health systems. Moreover, firms that can offer training, remote support, and integration with laboratory information systems reduce friction for customers and accelerate uptake. Competitive advantage increasingly hinges on the ability to deliver end-to-end solutions that address analytical performance, operational efficiency, and the practical realities of laboratory validation and clinician adoption.

Actionable recommendations for industry leaders to accelerate clinical adoption, fortify supply chains, optimize portfolios, and capture value across diagnostic segments

Industry leaders should prioritize a set of strategic actions that accelerate clinical adoption while managing operational risks. First, invest in targeted clinical utility studies that link diagnostic outputs to actionable treatment decisions and measurable patient outcomes; robust clinical evidence reduces payer resistance and supports broader uptake. Second, diversify supply chains and consider regional manufacturing or strategic inventory buffering to mitigate tariff and logistics risks, ensuring continuity of testing services during policy-driven disruptions.

Third, align product development with end-user workflows by offering modular platforms that support both high-throughput centralized testing and rapid point-of-care use cases. This approach increases addressable use cases while allowing laboratories to scale adoption according to capacity. Fourth, strengthen partnerships with reference laboratories and clinical networks to facilitate third-party validation, early use-case documentation, and clinician education that can accelerate adoption curves. Fifth, embed software-driven value propositions-such as connectivity, result interpretation, and workflow automation-into offerings to reduce laboratory burden and improve result utility for clinicians.

Finally, engage proactively with regulatory bodies and payers to clarify evidence expectations and reimbursement pathways early in development. By anticipating regulatory and reimbursement questions and incorporating real-world evidence collection into rollouts, companies can shorten time-to-market and reduce adoption friction. These actions, taken together, create a resilient commercial strategy that balances innovation, evidence generation, and operational continuity.

Transparent research methodology outlining primary and secondary research approaches, data triangulation, validation protocols, and limitations informing the analysis

The analysis is founded on a mixed-methods research approach that integrates primary qualitative inquiry with systematic secondary evidence review and triangulation. Primary research included structured interviews with clinical laboratorians, hospital procurement leaders, research institute investigators, and industry executives to capture experiential insights into workflows, validation barriers, and adoption drivers. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and technology white papers to contextualize primary findings and to verify analytical assumptions.

Data triangulation was employed to reconcile disparate inputs and to identify consistent patterns across stakeholder groups and evidence sources. Technology mapping and capability assessments were performed to align platform characteristics with clinical use cases and laboratory operational constraints. Additionally, a review of clinical trial registries and patent filings informed the forward-looking view on innovation trajectories and emerging assay modalities.

The research recognizes limitations inherent to qualitative and secondary data, including variability in regional reporting, evolving regulatory landscapes, and the lag between technological development and published clinical validation. To mitigate these limitations, the analysis emphasizes corroborated themes and distinguishes between observed practice and aspirational capabilities. Where appropriate, sensitivity to regional heterogeneity and institutional capacity has been maintained to ensure that recommendations are actionable across diverse healthcare contexts.

Concise conclusion synthesizing implications for clinicians, laboratory leaders, investors, and policymakers to navigate the evolving fungal diagnostics landscape

Fungal diagnostics are in a period of substantive evolution where technological innovation, supply chain realignment, and evidence-driven adoption converge to reshape clinical practice. Laboratories and healthcare organizations face a complex landscape of choices that must balance analytical performance with operational realities and payer expectations. As molecular and proteomic platforms mature and point-of-care modalities broaden access, success will favor solutions that demonstrate tangible clinical impact while integrating smoothly into existing workflows.

Policy and procurement variables, such as tariffs and regional manufacturing dynamics, will continue to influence investment and adoption patterns. Stakeholders that proactively address these factors through diversified sourcing, strategic partnerships, and focused evidence generation will preserve continuity of diagnostic services and accelerate innovation uptake. Ultimately, sustained progress will depend on collaborative approaches that link manufacturers, clinical leaders, and health systems in shared efforts to validate, implement, and optimize diagnostic pathways for fungal disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid molecular diagnostic panels into routine hospital workflows for fungal pathogens detection
  • 5.2. Adoption of next-generation sequencing for comprehensive identification of rare and drug-resistant fungal species
  • 5.3. Development of point-of-care immunoassays facilitating early detection of invasive fungal infections in outpatient settings
  • 5.4. Rising demand for multiplex PCR technologies enabling simultaneous detection of multiple fungal pathogens in clinical samples
  • 5.5. Expansion of telemedicine platforms incorporating remote diagnostic tools for monitoring chronic fungal infections
  • 5.6. Growing interest in lateral flow assays for bedside detection of cryptococcal antigen among HIV patients
  • 5.7. Regulatory approvals and reimbursement policies accelerating market access for novel beta-D-glucan diagnostic tests

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fungal Infections Diagnosis Market, by Diagnostic Technology

  • 8.1. Culture Based
    • 8.1.1. Liquid Broth Culture
    • 8.1.2. Solid Media Culture
  • 8.2. Immunoassays
    • 8.2.1. Elisa
    • 8.2.2. Lateral Flow Assay
  • 8.3. MALDI TOF MS
  • 8.4. Microscopy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Next Generation Sequencing
      • 8.5.1.1. Illumina Sequencing
      • 8.5.1.2. Ion Torrent Sequencing
    • 8.5.2. Polymerase Chain Reaction
      • 8.5.2.1. Conventional Polymerase Chain Reaction
      • 8.5.2.2. Real Time Polymerase Chain Reaction

9. Fungal Infections Diagnosis Market, by End User

  • 9.1. Diagnostic Laboratories
  • 9.2. Hospitals & Clinics
  • 9.3. Research Institutes

10. Fungal Infections Diagnosis Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid
  • 10.3. Sputum
  • 10.4. Tissue
  • 10.5. Urine

11. Fungal Infections Diagnosis Market, by Pathogen Type

  • 11.1. Aspergillosis
  • 11.2. Candidiasis
  • 11.3. Cryptococcosis
  • 11.4. Dermatophytosis
  • 11.5. Mucormycosis

12. Fungal Infections Diagnosis Market, by Testing Mode

  • 12.1. Laboratory Testing
  • 12.2. Point Of Care Testing
  • 12.3. Research Use Only

13. Fungal Infections Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fungal Infections Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fungal Infections Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Roche Holding AG
    • 16.3.3. Abbott Laboratories
    • 16.3.4. bioMerieux SA
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Bruker Corporation
    • 16.3.7. DiaSorin S.p.A.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Siemens Healthineers AG
    • 16.3.10. Fujirebio Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS